FDA asks Texas court to shut down 19 vaccine records lawsuit
Adds comment from FDA, plaintiff in paragraphs 7-9
By Mike Scarcella
Oct 18 (Reuters) -The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to COVID-19 vaccines, arguing that it has already spent more than $3.5 million to produce more than 1 million documents in the case.
The FDA in a filing on Thursday defended the adequacy of the records it provided in the lawsuit, which was filed by scientists who wanted to see licensing information that the agency relied on to approve the Pfizer-BioNTech coronavirus vaccine.
The lawsuit, filed in late 2021, attracted widespread attention after the FDA said early on that it could take decades to process and disclose records to Public Health and Medical Professionals for Transparency, the group that brought the case.
The public records lawsuit said that “the medical and scientific community and the public have a substantial interest in reviewing the data and information underlying the FDA’s approval of the Pfizer Vaccine.”
It said the requested data would help resolve questions about the FDA’s review process.
U.S. District Judge Mark Pittman in an order in early 2022 set an accelerated time frame for the FDA, calling the group's Freedom of Information Act request an issue “of paramount public importance.”
The FDA declined to comment.
Aaron Siri, a lawyer for Public Health and Medical Professionals for Transparency, in a statement on Friday said the fight for records was not over.
“Despite years of litigation, and the Court’s order to produce all clinical trial documents, FDA continues to improperly withhold over a million pages of trial documents," Siri said.
The agency at one point was producing 55,000 pages of records every 30 days in response to court orders in the lawsuit. It said in Thursday's filing seeking to close the case that it set up “unprecedented and extraordinary operations” to comply with Pittman’s directives.
Public Health and Medical Professionals for Transparency, whose members include professors and scientists from Yale, Harvard, UCLA and Brown, has posted thousands of records on its website.
Lawyers for the group said in a recent court filing that they would waive any further challenge to redactions that the FDA made in the more than 1.2 million documents released as part of the lawsuit.
The adequacy of the FDA’s search for records is the remaining contested issue in the lawsuit.
The FDA said it conducted a “reasonable and adequate search for responsive records.” The group is due to respond to the FDA by Nov. 7.
The case is Public Health and Medical Professionals for Transparency v. U.S. Food and Drug Administration, U.S. District Court for the Northern District of Texas, No. 4:21-cv-01058-P.
For plaintiff: Aaron Siri and ElizabethBrehm of Siri & Glimstad
For defendant: Andrew Freidah of the U.S. Justice Department
Read more:
Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA
‘Paramount importance’: Judge orders FDA to hasten release of Pfizer vaccine docs
Wait what? FDA wants 55 years to process FOIA request over vaccine data
Reporting by Mike Scarcella
Actifs liés
Dernières actualités
Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.
Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.
Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.
